Balchem Co. (NASDAQ:BCPC) Holdings Decreased by Pitcairn Co.

Pitcairn Co. cut its stake in shares of Balchem Co. (NASDAQ:BCPC) by 9.8% during the third quarter, HoldingsChannel.com reports. The firm owned 3,257 shares of the basic materials company’s stock after selling 355 shares during the period. Pitcairn Co.’s holdings in Balchem were worth $573,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. O Shaughnessy Asset Management LLC acquired a new position in shares of Balchem during the 1st quarter valued at about $321,000. Bessemer Group Inc. raised its position in shares of Balchem by 568.9% during the first quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock valued at $47,000 after buying an additional 256 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Balchem by 32.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 193,146 shares of the basic materials company’s stock valued at $29,929,000 after buying an additional 47,036 shares during the period. Janus Henderson Group PLC grew its position in Balchem by 21.3% during the first quarter. Janus Henderson Group PLC now owns 18,059 shares of the basic materials company’s stock worth $2,795,000 after buying an additional 3,176 shares in the last quarter. Finally, Tidal Investments LLC bought a new position in Balchem during the first quarter valued at about $265,000. 87.91% of the stock is currently owned by hedge funds and other institutional investors.

Balchem Stock Performance

NASDAQ BCPC opened at $182.69 on Tuesday. Balchem Co. has a twelve month low of $120.87 and a twelve month high of $186.03. The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21. The stock has a market cap of $5.94 billion, a P/E ratio of 49.11, a PEG ratio of 5.45 and a beta of 0.65. The company’s 50-day simple moving average is $173.84 and its 200 day simple moving average is $166.71.

Analysts Set New Price Targets

BCPC has been the subject of a number of research reports. StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a research report on Monday, October 28th. HC Wainwright raised their target price on Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, November 4th.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.